Moderna lays out plan for mRNA-1273 vaccine
Moderna released interim clinical data about mRNA-1273, its vaccine candidate against SARS-CoV-2, from the phase I study led by the U.S. National Institute of Allergy and Infectious Diseases. Based on the results, the company plans to begin a phase III study in July. Read More
Thermo Fisher gets U.S. contract for COVID-19 sample collection
Thermo Fisher Scientific announced that it has received a contract from the U.S. government to provide highly specialized viral transport media for COVID-19 sample collection. To fulfill the contract, the company will expand capacity with a $40 million facility. Read More
NantKwest scales up COVID-19 stem cell therapy
NantKwest announced that it received investigational new drug authorization from the U.S. Food and Drug Administration (FDA) to treat patients with acute respiratory distress syndrome caused by COVID-19 with BM-Allo MSC, an allogeneic mesenchymal stem cell product derived from human bone marrow. Read More
Codiak presents preclinical results for modular vaccine platform
Codiak BioSciences released new preclinical data on its engEx platform at the American Society of Gene and Cell Therapy annual meeting. Read More
Exyte, Univercells fast track construction for COVID-19 vaccines
High-tech construction firm Exyte and biomanufacturing company Univercells Technologies are partnering for construction of modular standardized and flexible manufacturing facilities for vaccines. Read More
Avrobio moves forward with gene therapy candidate
Avrobio released preclinical data for AVR-RD-03, lentiviral gene therapy for Pompe disease, at the American Society of Gene and Cell Therapy annual meeting on May 14. Read More
Glenmark begins phase III trials for favipiravir
Glenmark has launched phase III clinical trials in India to assess the use of its favipiravir antiviral tablets on COVID-19 patients. The drug is a generic version of Fujifilm Toyama Chemical's Avigan. Read More
Yumab identifies COVID-19 antibody therapy
German biotechnology company Yumab said it has identified a promising candidate for COVID-19 antibody therapy. Read More
BARDA gives $20M to Sabin Vaccine Institute for vaccines
The U.S. Biomedical Advanced Research and Development Authority (BARDA) awarded the Sabin Vaccine Institute $20 million to manufacture and release clinical Ebola and Marburg vaccine materials developed by its partner, ReiThera. The funding will also support nonclinical studies to evaluate their efficacy and immune response. Read More
Gilead licenses remdesivir to increase global access
Gilead Sciences has inked several agreements for the manufacture and distribution of remdesivir, which has been issued an emergency use authorization by the U.S. Food and Drug Administration (FDA) on May 1. Read More
Northeast Regional Laboratory Staff and Core Directors (NERLSCD) 2021
November 3-5
Portsmouth, New Hampshire United States
CPhI Worldwide 2021
November 9-11
Milan, Lombardia Italy
Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 10-14
Washington, DC, District of Columbia United States
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter